1
|
Liefeld T, Huang E, Wenzel AT, Yoshimoto K, Sharma AK, Sicklick JK, Mesirov JP, Reich M. NMF Clustering: Accessible NMF-based Clustering Utilizing GPU Acceleration. J Bioinform Syst Biol 2023; 6:379-383. [PMID: 38390437 PMCID: PMC10883375 DOI: 10.26502/jbsb.5107072] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 02/24/2024]
Abstract
Non-negative Matrix Factorization (NMF) is an algorithm that can reduce high dimensional datasets of tens of thousands of genes to a handful of metagenes which are biologically easier to interpret. Application of NMF on gene expression data has been limited by its computationally intensive nature, which hinders its use on large datasets such as single-cell RNA sequencing (scRNA-seq) count matrices. We have implemented NMF based clustering to run on high performance GPU compute nodes using CuPy, a GPU backed python library, and the Message Passing Interface (MPI). This reduces the computation time by up to three orders of magnitude and makes the NMF Clustering analysis of large RNA-Seq and scRNA-seq datasets practical. We have made the method freely available through the GenePattern gateway, which provides free public access to hundreds of tools for the analysis and visualization of multiple 'omic data types. Its web-based interface gives easy access to these tools and allows the creation of multi-step analysis pipelines on high performance computing (HPC) clusters that enable reproducible in silico research for non-programmers.
Collapse
Affiliation(s)
- Ted Liefeld
- University of California San Diego, Department of Medicine, School of Medicine, La Jolla, CA, 92093, USA
| | - Edwin Huang
- University of California San Diego, Department of Medicine, School of Medicine, La Jolla, CA, 92093, USA
| | - Alexander T Wenzel
- University of California San Diego, Department of Medicine, School of Medicine, La Jolla, CA, 92093, USA
| | - Kenneth Yoshimoto
- University of California San Diego, San Diego Supercomputer Center, La Jolla, CA, 92093, USA
| | - Ashwyn K Sharma
- University of California San Diego, Moores Cancer Center, La Jolla, CA, 92093, USA
| | - Jason K Sicklick
- University of California San Diego, Departments of Surgery and Pharmacology, Moores Cancer Center,La Jolla, CA, 92093, USA
| | - Jill P Mesirov
- University of California San Diego, Department of Medicine, School of Medicine, La Jolla, CA, 92093, USA
- University of California San Diego, Moores Cancer Center, La Jolla, CA, 92093, USA
| | - Michael Reich
- University of California San Diego, Department of Medicine, School of Medicine, La Jolla, CA, 92093, USA
| |
Collapse
|
2
|
Wu VH, Yung BS, Faraji F, Saddawi-Konefka R, Wang Z, Wenzel AT, Song MJ, Pagadala MS, Clubb LM, Chiou J, Sinha S, Matic M, Raimondi F, Hoang TS, Berdeaux R, Vignali DAA, Iglesias-Bartolome R, Carter H, Ruppin E, Mesirov JP, Gutkind JS. The GPCR-Gα s-PKA signaling axis promotes T cell dysfunction and cancer immunotherapy failure. Nat Immunol 2023; 24:1318-1330. [PMID: 37308665 PMCID: PMC10735169 DOI: 10.1038/s41590-023-01529-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/08/2021] [Accepted: 05/06/2023] [Indexed: 06/14/2023]
Abstract
Immune checkpoint blockade (ICB) targeting PD-1 and CTLA-4 has revolutionized cancer treatment. However, many cancers do not respond to ICB, prompting the search for additional strategies to achieve durable responses. G-protein-coupled receptors (GPCRs) are the most intensively studied drug targets but are underexplored in immuno-oncology. Here, we cross-integrated large singe-cell RNA-sequencing datasets from CD8+ T cells covering 19 distinct cancer types and identified an enrichment of Gαs-coupled GPCRs on exhausted CD8+ T cells. These include EP2, EP4, A2AR, β1AR and β2AR, all of which promote T cell dysfunction. We also developed transgenic mice expressing a chemogenetic CD8-restricted Gαs-DREADD to activate CD8-restricted Gαs signaling and show that a Gαs-PKA signaling axis promotes CD8+ T cell dysfunction and immunotherapy failure. These data indicate that Gαs-GPCRs are druggable immune checkpoints that might be targeted to enhance the response to ICB immunotherapies.
Collapse
Affiliation(s)
- Victoria H Wu
- Department of Pharmacology, UCSD Moores Cancer Center, University of California, San Diego, La Jolla, CA, USA
- Septerna, Inc., South San Francisco, CA, USA
| | - Bryan S Yung
- Department of Pharmacology, UCSD Moores Cancer Center, University of California, San Diego, La Jolla, CA, USA
| | - Farhoud Faraji
- Department of Otolaryngology-Head and Neck Surgery, University of California San Diego Health, La Jolla, CA, USA
- UCSD Moores Cancer Center, University of California, San Diego, La Jolla, CA, USA
| | - Robert Saddawi-Konefka
- Department of Otolaryngology-Head and Neck Surgery, University of California San Diego Health, La Jolla, CA, USA
- UCSD Moores Cancer Center, University of California, San Diego, La Jolla, CA, USA
| | - Zhiyong Wang
- UCSD Moores Cancer Center, University of California, San Diego, La Jolla, CA, USA
| | - Alexander T Wenzel
- UCSD Moores Cancer Center, University of California, San Diego, La Jolla, CA, USA
- Department of Medicine, University of California, San Diego, La Jolla, CA, USA
| | - Miranda J Song
- UCSD Moores Cancer Center, University of California, San Diego, La Jolla, CA, USA
- Department of Medicine, University of California, San Diego, La Jolla, CA, USA
| | - Meghana S Pagadala
- Department of Medicine, University of California, San Diego, La Jolla, CA, USA
| | - Lauren M Clubb
- Department of Pharmacology, UCSD Moores Cancer Center, University of California, San Diego, La Jolla, CA, USA
| | - Joshua Chiou
- Biomedical Sciences Graduate Studies Program, University of California, San Diego, La Jolla, CA, USA
- Internal Medicine Research Unit, Pfizer Worldwide Research, Cambridge, MA, USA
| | - Sanju Sinha
- Cancer Data Science Laboratory, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA
| | - Marin Matic
- Laboratorio di Biologia Bio@SNS, Scuola Normale Superiore, Pisa, Italy
| | | | - Thomas S Hoang
- Department of Pharmacology, UCSD Moores Cancer Center, University of California, San Diego, La Jolla, CA, USA
| | - Rebecca Berdeaux
- Department of Integrative Biology and Pharmacology, McGovern Medical School at UT Health Houston and CellChorus INC, Houston, TX, USA
| | - Dario A A Vignali
- Department of Immunology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA
- Tumor Microenvironment Center, UPMC Hillman Cancer Center, Pittsburgh, PA, USA
- Cancer Immunology and Immunotherapy Program, UPMC Hillman Cancer Center, Pittsburgh, PA, USA
| | - Ramiro Iglesias-Bartolome
- Laboratory of Cellular and Molecular Biology, Center for Cancer Research, National Cancer Institute, National Institute of Health, Bethesda, MD, USA
| | - Hannah Carter
- UCSD Moores Cancer Center, University of California, San Diego, La Jolla, CA, USA
- Department of Medicine, University of California, San Diego, La Jolla, CA, USA
| | - Eytan Ruppin
- Cancer Data Science Laboratory, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA
| | - Jill P Mesirov
- UCSD Moores Cancer Center, University of California, San Diego, La Jolla, CA, USA
- Department of Medicine, University of California, San Diego, La Jolla, CA, USA
| | - J Silvio Gutkind
- Department of Pharmacology, UCSD Moores Cancer Center, University of California, San Diego, La Jolla, CA, USA.
| |
Collapse
|
3
|
Liefeld T, Huang E, Wenzel AT, Yoshimoto K, Sharma AK, Sicklick JK, Mesirov JP, Reich M. NMFClustering: Accessible NMF-based clustering utilizing GPU acceleration. bioRxiv 2023:2023.06.16.545370. [PMID: 37398372 PMCID: PMC10312797 DOI: 10.1101/2023.06.16.545370] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 07/04/2023]
Abstract
Non-negative Matrix Factorization (NME) is an algorithm that can reduce high dimensional datasets of tens of thousands of genes to a handful of metagenes which are biologically easier to interpret. Application of NMF on gene expression data has been limited by its computationally intensive nature, which hinders its use on large datasets such as single-cell RNA sequencing (scRNA-seq) count matrices. We have implemented NMF based clustering to run on high performance GPU compute nodes using Cupy, a GPU backed python library, and the Message Passing Interface (MPI). This reduces the computation time by up to three orders of magnitude and makes the NMF Clustering analysis of large RNA-Seq and scRNA-seq datasets practical. We have made the method freely available through the GenePatten gateway, which provides free public access to hundreds of tools for the analysis and visualization of multiple 'omic data types. Its web-based interface gives easy access to these tools and allows the creation of multi-step analysis pipelnes on high performance computing (HPC) culsters that enable reproducible in silco research for non-programmers.
Collapse
Affiliation(s)
- Ted Liefeld
- University of California San Diego, Department of Medicine, School of Medicine, La Jolla, CA, 92093, USA
| | - Edwin Huang
- University of California San Diego, Department of Medicine, School of Medicine, La Jolla, CA, 92093, USA
| | - Alexander T Wenzel
- University of California San Diego, Department of Medicine, School Of Medicine, La Jolla, CA, 92093, USA
| | - Kenneth Yoshimoto
- University of California San Diego, San Diego Supercomputer Center, La Jolla, CA, 92093, USA
| | - Ashwyn K Sharma
- University of California San Diego, Moores Cancer Center, La Jolla, CA, 92093, USA
| | - Jason K Sicklick
- University of California San Diego, Departments of Surgery and Pharmacology, Moores Cancer Center, La Jolla, CA, 92093, USA
| | - Jill P Mesirov
- University of California San Diego, Department of Medicine, School of Medicine, La Jolla, CA, 92093, USA
- University of California San Diego, Moores Cancer Center, La Jolla, CA, 92093, USA
| | - Michael Reich
- University of California San Diego, Department of Medicine, School of Medicine, La Jolla, CA, 92093, USA
| |
Collapse
|
4
|
Wenzel AT, Tamayo P, Mesirov JP. Abstract 4281: Data driven refinement of gene signatures for enrichment analysis and cell state characterization. Cancer Res 2023. [DOI: 10.1158/1538-7445.am2023-4281] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 04/07/2023]
Abstract
Abstract
The use of gene expression data has been crucial to the functional characterization of changes in molecular pathway activity and for identifying targets for novel treatments. However, the interpretation of this data is complicated by its high dimensionality and the difficulty of identifying biological signals within a list of differentially expressed genes. Gene Set Enrichment Analysis (GSEA) is a standard method for identifying pathway enrichment in gene expression data by testing whether a set of genes whose expression would indicate the activity of a specific process or phenotype are coordinately up- or downregulated more than would be expected by chance. As GSEA relies on high quality gene sets with coordinately regulated member genes, we maintain the Molecular Signatures Database (MSigDB) which contains 9 collections of curated gene sets representing different biological pathways and processes. Over time, we have observed that some of the MSigDB gene sets, especially those that are manually curated or defined in a very specific biological context, may not provide a sensitive and specific enough co-regulation signature. In response, we have created a data-driven, matrix-factorization-based refinement method to build more sensitive and specific gene sets. This method incorporates large-scale datasets from multiple sources such as the Cancer Dependency Map as well as curated protein-protein interaction networks. We will present the initial results of this refinement method and our ongoing work which will yield a new collection of refined gene sets that will be made freely available in MSigDB for use with GSEA and many other applications.
Citation Format: Alexander T. Wenzel, Pablo Tamayo, Jill P. Mesirov. Data driven refinement of gene signatures for enrichment analysis and cell state characterization. [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2023; Part 1 (Regular and Invited Abstracts); 2023 Apr 14-19; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2023;83(7_Suppl):Abstract nr 4281.
Collapse
|
5
|
Aronoff-Spencer E, Nebeker C, Wenzel AT, Nguyen K, Kunowski R, Zhu M, Adamos G, Goyal R, Mazrouee S, Reyes A, May N, Howard H, Longhurst CA, Malekinejad M. Defining Key Performance Indicators for the California COVID-19 Exposure Notification System (CA Notify). Public Health Rep 2022; 137:67S-75S. [PMID: 36314660 PMCID: PMC9678789 DOI: 10.1177/00333549221129354] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022] Open
Abstract
OBJECTIVES Toward common methods for system monitoring and evaluation, we proposed a key performance indicator framework and discussed lessons learned while implementing a statewide exposure notification (EN) system in California during the COVID-19 epidemic. MATERIALS AND METHODS California deployed the Google Apple Exposure Notification framework, branded CA Notify, on December 10, 2020, to supplement traditional COVID-19 contact tracing programs. For system evaluation, we defined 6 key performance indicators: adoption, retention, sharing of unique codes, identification of potential contacts, behavior change, and impact. We aggregated and analyzed data from December 10, 2020, to July 1, 2021, in compliance with the CA Notify privacy policy. RESULTS We estimated CA Notify adoption at nearly 11 million smartphone activations during the study period. Among 1 654 201 CA Notify users who received a positive test result for SARS-CoV-2, 446 634 (27%) shared their unique code, leading to ENs for other CA Notify users who were in close proximity to the SARS-CoV-2-positive individual. We identified at least 122 970 CA Notify users as contacts through this process. Contact identification occurred a median of 4 days after symptom onset or specimen collection date of the user who received a positive test result for SARS-CoV-2. PRACTICE IMPLICATIONS Smartphone-based EN systems are promising new tools to supplement traditional contact tracing and public health interventions, particularly when efficient scaling is not feasible for other approaches. Methods to collect and interpret appropriate measures of system performance must be refined while maintaining trust and privacy.
Collapse
Affiliation(s)
- Eliah Aronoff-Spencer
- Division of Infectious Diseases and Global Public Health, School of Medicine, University of California San Diego, La Jolla, CA, USA
- University of California San Diego Health, La Jolla, CA, USA
- The Design Lab, University of California San Diego, La Jolla, CA, USA
| | - Camille Nebeker
- The Design Lab, University of California San Diego, La Jolla, CA, USA
- Herbert Wertheim School of Public Health and Human Longevity Science, University of California San Diego, La Jolla, CA, USA
| | - Alexander T. Wenzel
- Department of Biomedical Informatics, School of Medicine, University of California San Diego, La Jolla, CA, USA
| | - Kevin Nguyen
- University of California San Diego Health, La Jolla, CA, USA
- Herbert Wertheim School of Public Health and Human Longevity Science, University of California San Diego, La Jolla, CA, USA
| | - Rachel Kunowski
- University of California San Diego Health, La Jolla, CA, USA
| | - Mingjia Zhu
- University of California San Diego Health, La Jolla, CA, USA
| | - Gary Adamos
- University of California San Diego Health, La Jolla, CA, USA
| | - Ravi Goyal
- Division of Infectious Diseases and Global Public Health, School of Medicine, University of California San Diego, La Jolla, CA, USA
| | - Sepideh Mazrouee
- Division of Infectious Diseases and Global Public Health, School of Medicine, University of California San Diego, La Jolla, CA, USA
| | - Aaron Reyes
- University of California San Diego Health, La Jolla, CA, USA
| | - Nicole May
- University of California San Diego Health, La Jolla, CA, USA
| | - Holly Howard
- California Connected, Center for Infectious Diseases, California Department of Public Health, Richmond, CA, USA
- Institute for Global Health Sciences, University of California San Francisco, San Francisco, CA, USA
| | - Christopher A. Longhurst
- Department of Biomedical Informatics, School of Medicine, University of California San Diego, La Jolla, CA, USA
- Department of Pediatrics, School of Medicine, University of California San Diego, La Jolla, CA, USA
| | - Mohsen Malekinejad
- California Connected, Center for Infectious Diseases, California Department of Public Health, Richmond, CA, USA
- Institute for Global Health Sciences, University of California San Francisco, San Francisco, CA, USA
- Department of Epidemiology and Biostatistics, University of California San Francisco, San Francisco, CA, USA
| |
Collapse
|
6
|
Wenzel AT, Tamayo P, Mesirov JP. Abstract 5032: Data driven refinement of gene signatures for enrichment analysis and cell state characterization. Cancer Res 2022. [DOI: 10.1158/1538-7445.am2022-5032] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
In the study of human disease, the use of gene expression data has been crucial to the functional characterization of changes in molecular pathway activity and for identifying targets for novel treatments. However, the interpretation of this data is often complicated by its high dimensionality and the difficulty of identifying biological signals within a list of differentially expressed genes. Gene Set Enrichment Analysis (GSEA) is a community standard method for identifying pathway enrichment in gene expression data by testing whether a set of genes whose expression would indicate the activity of a specific process or phenotype are coordinately up- or downregulated more than would be expected by chance. As GSEA relies on high quality gene sets with coordinately regulated member genes, we maintain the Molecular Signatures Database (MSigDB) which contains 9 collections of curated, annotated gene sets representing different biological pathways and processes. Over time, we have observed that some of the MSigDB gene sets, especially those that are manually curated or defined in a very specific biological context, may not provide a sensitive and specific enough co-regulation signature for their corresponding phenotype. In response, we have created a data-driven, matrix-factorization-based refinement method to build more sensitive and specific gene sets. This method incorporates large-scale datasets from multiple sources including compendia such as the Cancer Dependency Map as well as curated protein-protein interaction networks. We will present the initial results of this refinement method as well as our ongoing work which will yield a new collection of refined gene sets that will be made freely available in MSigDB for use with GSEA and many other applications.
Citation Format: Alexander T. Wenzel, Pablo Tamayo, Jill P. Mesirov. Data driven refinement of gene signatures for enrichment analysis and cell state characterization [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl):Abstract nr 5032.
Collapse
Affiliation(s)
| | - Pablo Tamayo
- 1University of California, San Diego, San Diego, CA
| | | |
Collapse
|
7
|
Banerjee S, Yoon H, Ting S, Tang CM, Yebra M, Wenzel AT, Yeerna H, Mesirov JP, Wechsler-Reya RJ, Tamayo P, Sicklick JK. KIT low Cells Mediate Imatinib Resistance in Gastrointestinal Stromal Tumor. Mol Cancer Ther 2021; 20:2035-2048. [PMID: 34376580 PMCID: PMC8492542 DOI: 10.1158/1535-7163.mct-20-0973] [Citation(s) in RCA: 9] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/20/2020] [Revised: 04/06/2021] [Accepted: 06/30/2021] [Indexed: 11/16/2022]
Abstract
Gastrointestinal stromal tumor (GIST) is commonly driven by oncogenic KIT mutations that are effectively targeted by imatinib (IM), a tyrosine kinase inhibitor (TKI). However, IM does not cure GIST, and adjuvant therapy only delays recurrence in high-risk tumors. We hypothesized that GIST contains cells with primary IM resistance that may represent a reservoir for disease persistence. Here, we report a subpopulation of CD34+KITlow human GIST cells that have intrinsic IM resistance. These cells possess cancer stem cell-like expression profiles and behavior, including self-renewal and differentiation into CD34+KIThigh progeny that are sensitive to IM treatment. We also found that TKI treatment of GIST cell lines led to induction of stem cell-associated transcription factors (OCT4 and NANOG) and concomitant enrichment of the CD34+KITlow cell population. Using a data-driven approach, we constructed a transcriptomic-oncogenic map (Onco-GPS) based on the gene expression of 134 GIST samples to define pathway activation during GIST tumorigenesis. Tumors with low KIT expression had overexpression of cancer stem cell gene signatures consistent with our in vitro findings. Additionally, these tumors had activation of the Gas6/AXL pathway and NF-κB signaling gene signatures. We evaluated these targets in vitro and found that primary IM-resistant GIST cells were effectively targeted with either single-agent bemcentinib (AXL inhibitor) or bardoxolone (NF-κB inhibitor), as well as with either agent in combination with IM. Collectively, these findings suggest that CD34+KITlow cells represent a distinct, but targetable, subpopulation in human GIST that may represent a novel mechanism of primary TKI resistance, as well as a target for overcoming disease persistence following TKI therapy.
Collapse
Affiliation(s)
- Sudeep Banerjee
- Department of Surgery, Division of Surgical Oncology, University of California, San Diego, California
- Department of Surgery, University of California, Los Angeles, California
- Moores Cancer Center, University of California, San Diego, California
| | - Hyunho Yoon
- Department of Surgery, Division of Surgical Oncology, University of California, San Diego, California
- Moores Cancer Center, University of California, San Diego, California
- Department of Medical and Biological Sciences, The Catholic University of Korea, Bucheon, Republic of Korea
| | - Stephanie Ting
- Moores Cancer Center, University of California, San Diego, California
- Department of Medicine, Division of Medical Genetics, University of California, San Diego, California
| | - Chih-Min Tang
- Department of Surgery, Division of Surgical Oncology, University of California, San Diego, California
- Moores Cancer Center, University of California, San Diego, California
| | - Mayra Yebra
- Department of Surgery, Division of Surgical Oncology, University of California, San Diego, California
- Moores Cancer Center, University of California, San Diego, California
| | - Alexander T Wenzel
- Moores Cancer Center, University of California, San Diego, California
- Department of Medicine, Division of Medical Genetics, University of California, San Diego, California
| | - Huwate Yeerna
- Moores Cancer Center, University of California, San Diego, California
- Department of Medicine, Division of Medical Genetics, University of California, San Diego, California
| | - Jill P Mesirov
- Moores Cancer Center, University of California, San Diego, California
- Department of Medicine, Division of Medical Genetics, University of California, San Diego, California
| | | | - Pablo Tamayo
- Moores Cancer Center, University of California, San Diego, California
- Department of Medicine, Division of Medical Genetics, University of California, San Diego, California
- UCSD Center for Novel Therapeutics, La Jolla, California
| | - Jason K Sicklick
- Department of Surgery, Division of Surgical Oncology, University of California, San Diego, California.
- Moores Cancer Center, University of California, San Diego, California
| |
Collapse
|
8
|
Richelle A, Kellman BP, Wenzel AT, Chiang AW, Reagan T, Gutierrez JM, Joshi C, Li S, Liu JK, Masson H, Lee J, Li Z, Heirendt L, Trefois C, Juarez EF, Bath T, Borland D, Mesirov JP, Robasky K, Lewis NE. Model-based assessment of mammalian cell metabolic functionalities using omics data. Cell Rep Methods 2021; 1:100040. [PMID: 34761247 PMCID: PMC8577426 DOI: 10.1016/j.crmeth.2021.100040] [Citation(s) in RCA: 12] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 02/12/2021] [Revised: 04/24/2021] [Accepted: 05/24/2021] [Indexed: 12/30/2022]
Abstract
Omics experiments are ubiquitous in biological studies, leading to a deluge of data. However, it is still challenging to connect changes in these data to changes in cell functions because of complex interdependencies between genes, proteins, and metabolites. Here, we present a framework allowing researchers to infer how metabolic functions change on the basis of omics data. To enable this, we curated and standardized lists of metabolic tasks that mammalian cells can accomplish. Genome-scale metabolic networks were used to define gene sets associated with each metabolic task. We further developed a framework to overlay omics data on these sets and predict pathway usage for each metabolic task. We demonstrated how this approach can be used to quantify metabolic functions of diverse biological samples from the single cell to whole tissues and organs by using multiple transcriptomic datasets. To facilitate its adoption, we integrated the approach into GenePattern (www.genepattern.org-CellFie).
Collapse
Affiliation(s)
- Anne Richelle
- Novo Nordisk Foundation Center for Biosustainability at the University of California, San Diego, School of Medicine, La Jolla, CA 92093, USA
- Department of Pediatrics, University of California, San Diego, School of Medicine, La Jolla, CA 92093, USA
| | - Benjamin P. Kellman
- Department of Pediatrics, University of California, San Diego, School of Medicine, La Jolla, CA 92093, USA
- Bioinformatics and Systems Biology Program, University of California, San Diego, La Jolla, CA 92093, USA
| | - Alexander T. Wenzel
- Bioinformatics and Systems Biology Program, University of California, San Diego, La Jolla, CA 92093, USA
- Department of Medicine, University of California, San Diego, School of Medicine, La Jolla, CA 92093, USA
- Moores Cancer Center, University of California, San Diego, La Jolla, CA 92093, USA
| | - Austin W.T. Chiang
- Novo Nordisk Foundation Center for Biosustainability at the University of California, San Diego, School of Medicine, La Jolla, CA 92093, USA
- Department of Pediatrics, University of California, San Diego, School of Medicine, La Jolla, CA 92093, USA
| | - Tyler Reagan
- Department of Pediatrics, University of California, San Diego, School of Medicine, La Jolla, CA 92093, USA
| | - Jahir M. Gutierrez
- Department of Bioengineering, University of California, San Diego, La Jolla, CA 92093, USA
| | - Chintan Joshi
- Novo Nordisk Foundation Center for Biosustainability at the University of California, San Diego, School of Medicine, La Jolla, CA 92093, USA
- Department of Pediatrics, University of California, San Diego, School of Medicine, La Jolla, CA 92093, USA
| | - Shangzhong Li
- Novo Nordisk Foundation Center for Biosustainability at the University of California, San Diego, School of Medicine, La Jolla, CA 92093, USA
- Department of Bioengineering, University of California, San Diego, La Jolla, CA 92093, USA
| | - Joanne K. Liu
- Bioinformatics and Systems Biology Program, University of California, San Diego, La Jolla, CA 92093, USA
| | - Helen Masson
- Novo Nordisk Foundation Center for Biosustainability at the University of California, San Diego, School of Medicine, La Jolla, CA 92093, USA
- Department of Bioengineering, University of California, San Diego, La Jolla, CA 92093, USA
| | - Jooyong Lee
- Novo Nordisk Foundation Center for Biosustainability at the University of California, San Diego, School of Medicine, La Jolla, CA 92093, USA
- Department of Pediatrics, University of California, San Diego, School of Medicine, La Jolla, CA 92093, USA
| | - Zerong Li
- Department of Computer Science and Engineering, University of California, San Diego, La Jolla, CA 92093, USA
| | - Laurent Heirendt
- Luxembourg Centre for Systems Biomedicine, University of Luxembourg, Esch-sur-Alzette, Luxembourg
| | - Christophe Trefois
- Luxembourg Centre for Systems Biomedicine, University of Luxembourg, Esch-sur-Alzette, Luxembourg
| | - Edwin F. Juarez
- Department of Medicine, University of California, San Diego, School of Medicine, La Jolla, CA 92093, USA
- Moores Cancer Center, University of California, San Diego, La Jolla, CA 92093, USA
| | - Tyler Bath
- Department of Biomedical Informatics, UC San Diego Health, University of California, San Diego, La Jolla, CA 92093, USA
| | - David Borland
- Renaissance Computing Institute, The University of North Carolina at Chapel Hill, Chapel Hill, NC 27517, USA
| | - Jill P. Mesirov
- Department of Medicine, University of California, San Diego, School of Medicine, La Jolla, CA 92093, USA
- Moores Cancer Center, University of California, San Diego, La Jolla, CA 92093, USA
| | - Kimberly Robasky
- Renaissance Computing Institute, The University of North Carolina at Chapel Hill, Chapel Hill, NC 27517, USA
- Department of Genetics, University of North Carolina at Chapel Hill, Chapel Hill, NC 27514, USA
- School of Information and Library Science, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA
- Carolina Health and Informatics Program, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA
| | - Nathan E. Lewis
- Novo Nordisk Foundation Center for Biosustainability at the University of California, San Diego, School of Medicine, La Jolla, CA 92093, USA
- Department of Pediatrics, University of California, San Diego, School of Medicine, La Jolla, CA 92093, USA
- Department of Bioengineering, University of California, San Diego, La Jolla, CA 92093, USA
| |
Collapse
|
9
|
Wenzel AT, Champa D, Howell SB, Mesirov JP, Harismendy O. Abstract 4411: A gene set enrichment analysis approach in single-cells along pseudotime trajectories reveals the dynamic activity of oncogenic pathways. Cancer Res 2020. [DOI: 10.1158/1538-7445.am2020-4411] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Single cell RNA-sequencing (scRNA-seq) has advanced studies of heterogeneous tissues and cell populations in both healthy and disease states. Dimensionality reduction methods leverage this highly granular data to identify cellular states not captured by “bulk” gene expression or to organize cells along ‘pseudotime' trajectories related to biological processes such as cell cycle or cellular differentiation. Cellular states and trajectories are often annotated using individual marker genes and not gene sets or pathways, despite their more reliable and interpretable association to biological processes. Gene Set Enrichment Analysis (GSEA) was designed to test the enrichment of gene sets in bulk transcriptomic data, but due to the sparsity of the expression data, has not been adapted to single cell analysis. We propose a method to compute gene set enrichment for scRNA-seq data, which calculates an enrichment score for each cell in the dataset. We apply this method to a set of matched ovarian cancer cell lines with acquired resistance to carboplatin. After aligning the cells to a cell-cycle derived pseudotime trajectory, the activity of pathways which were dysregulated in bulk expression profiles appeared to change with the cell cycle progression. The analysis further identified interferon alpha signaling induction in resistant cells, independent of differences in cell cycle progression. Hence, by quantifying and analyzing pathway-level transcriptional activity in the context of a single-cell pseudotime trajectory, the proposed method provides more interpretable annotation of biological processes altered in cancer progression and treatment.
Citation Format: Alexander T. Wenzel, Devora Champa, Stephen B. Howell, Jill P. Mesirov, Olivier Harismendy. A gene set enrichment analysis approach in single-cells along pseudotime trajectories reveals the dynamic activity of oncogenic pathways [abstract]. In: Proceedings of the Annual Meeting of the American Association for Cancer Research 2020; 2020 Apr 27-28 and Jun 22-24. Philadelphia (PA): AACR; Cancer Res 2020;80(16 Suppl):Abstract nr 4411.
Collapse
|
10
|
Mah CK, Wenzel AT, Juarez EF, Tabor T, Reich MM, Mesirov JP. An accessible, interactive GenePattern Notebook for analysis and exploration of single-cell transcriptomic data. F1000Res 2019; 7:1306. [PMID: 31316748 PMCID: PMC6611141 DOI: 10.12688/f1000research.15830.2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Accepted: 05/09/2019] [Indexed: 11/20/2022] Open
Abstract
Single-cell RNA sequencing (scRNA-seq) has emerged as a popular method to profile gene expression at the resolution of individual cells. While there have been methods and software specifically developed to analyze scRNA-seq data, they are most accessible to users who program. We have created a scRNA-seq clustering analysis GenePattern Notebook that provides an interactive, easy-to-use interface for data analysis and exploration of scRNA-Seq data, without the need to write or view any code. The notebook provides a standard scRNA-seq analysis workflow for pre-processing data, identification of sub-populations of cells by clustering, and exploration of biomarkers to characterize heterogeneous cell populations and delineate cell types.
Collapse
Affiliation(s)
- Clarence K Mah
- Department of Medicine, University of California, San Diego, La Jolla, CA, 92093, USA
| | - Alexander T Wenzel
- Department of Medicine, University of California, San Diego, La Jolla, CA, 92093, USA
| | - Edwin F Juarez
- Department of Medicine, University of California, San Diego, La Jolla, CA, 92093, USA
| | - Thorin Tabor
- Department of Medicine, University of California, San Diego, La Jolla, CA, 92093, USA
| | - Michael M Reich
- Department of Medicine, University of California, San Diego, La Jolla, CA, 92093, USA
| | - Jill P Mesirov
- Department of Medicine, University of California, San Diego, La Jolla, CA, 92093, USA.,Moores Cancer Center, University of California, San Diego, La Jolla, CA, 92093, USA
| |
Collapse
|
11
|
Yélamos O, Merkel EA, Sholl LM, Zhang B, Amin SM, Lee CY, Guitart GE, Yang J, Wenzel AT, Bunick CG, Yazdan P, Choi J, Gerami P. Nonoverlapping Clinical and Mutational Patterns in Melanomas from the Female Genital Tract and Atypical Genital Nevi. J Invest Dermatol 2016; 136:1858-1865. [PMID: 27220476 DOI: 10.1016/j.jid.2016.05.094] [Citation(s) in RCA: 18] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/10/2015] [Revised: 04/20/2016] [Accepted: 05/03/2016] [Indexed: 01/17/2023]
Abstract
Genital melanomas (GM) are the second most common cancer of the female external genitalia and may be confused with atypical genital nevi (AGN), which exhibit atypical histological features but have benign behavior. In this study, we compared the clinical, histological, and molecular features of 19 GM and 25 AGN. We described chromosomal copy number aberrations and the mutational status of 50 oncogenes and tumor suppressor genes in both groups. Our study showed that a pigmented lesion occurring in mucosal tissue, particularly in postmenopausal women, was more likely to be a melanoma than a nevus. GM had high levels of chromosomal instability, with many copy number aberrations. Furthermore, we found a completely nonoverlapping pattern of oncogenic mutations when comparing GM and AGN. In GM, we report somatic mutations in KIT and TP53. Conversely, AGN had frequent BRAF V600E mutations, which were not seen in any of the GM. Our results show that GM and AGN have distinct clinical and molecular changes and that GM have a different mutational pattern compared with AGN.
Collapse
Affiliation(s)
- Oriol Yélamos
- Department of Dermatology, Feinberg School of Medicine, Northwestern University, Chicago, Illinois, USA
| | - Emily A Merkel
- Department of Dermatology, Feinberg School of Medicine, Northwestern University, Chicago, Illinois, USA
| | - Lauren Meldi Sholl
- Department of Dermatology, Feinberg School of Medicine, Northwestern University, Chicago, Illinois, USA
| | - Bin Zhang
- Department of Dermatology, Feinberg School of Medicine, Northwestern University, Chicago, Illinois, USA
| | - Sapna M Amin
- Department of Dermatology, Feinberg School of Medicine, Northwestern University, Chicago, Illinois, USA
| | - Christina Y Lee
- Department of Dermatology, Feinberg School of Medicine, Northwestern University, Chicago, Illinois, USA
| | - Gerta E Guitart
- Department of Dermatology, Feinberg School of Medicine, Northwestern University, Chicago, Illinois, USA
| | - Jingyi Yang
- Department of Dermatology, Feinberg School of Medicine, Northwestern University, Chicago, Illinois, USA
| | - Alexander T Wenzel
- Department of Dermatology, Feinberg School of Medicine, Northwestern University, Chicago, Illinois, USA
| | | | - Pedram Yazdan
- Department of Dermatology, Feinberg School of Medicine, Northwestern University, Chicago, Illinois, USA
| | - Jaehyuk Choi
- Department of Dermatology, Feinberg School of Medicine, Northwestern University, Chicago, Illinois, USA; Department of Biochemistry and Molecular Genetics, Feinberg School of Medicine, Northwestern University, Chicago, Illinois, USA
| | - Pedram Gerami
- Department of Dermatology, Feinberg School of Medicine, Northwestern University, Chicago, Illinois, USA; Robert H. Lurie Cancer Center, Feinberg School of Medicine, Northwestern University, Chicago, Illinois, USA.
| |
Collapse
|